Compare ZVRA & FAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZVRA | FAX |
|---|---|---|
| Founded | 2006 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.2M | 599.0M |
| IPO Year | 2015 | N/A |
| Metric | ZVRA | FAX |
|---|---|---|
| Price | $9.82 | $14.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 117.6K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.09% |
| EPS Growth | ★ 159.21 | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $106,470,000.00 | N/A |
| Revenue This Year | $37.27 | N/A |
| Revenue Next Year | $53.42 | N/A |
| P/E Ratio | $15.85 | ★ N/A |
| Revenue Growth | ★ 350.91 | N/A |
| 52 Week Low | $7.16 | $14.13 |
| 52 Week High | $15.04 | $16.90 |
| Indicator | ZVRA | FAX |
|---|---|---|
| Relative Strength Index (RSI) | 32.87 | 47.47 |
| Support Level | $9.53 | $14.18 |
| Resistance Level | $11.07 | $14.70 |
| Average True Range (ATR) | 0.56 | 0.16 |
| MACD | -0.33 | -0.01 |
| Stochastic Oscillator | 17.33 | 27.66 |
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.